ClinicalTrials.gg
Enrolling by invitationNCT06458426Updated May 14, 2026

Thermoregulation in Individuals With a Leg Amputation

An interventional study of shock-absorbing prosthesis in Amputation and Diabetes, sponsored by University of Utah. Enrolling by invitation at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University of Utah · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Diabetes Mellitus by University of Utah — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus · University of Utah.

Planned enrollment
9th of 12
60 · median 100
Started
2024
the only one that year
No phase
11 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Diabetes Mellitus by University of Utah, this one is the 9th largest by planned enrollment, is the only one that started in 2024, is one of 11 with no phase, and was the 12th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 12 studies in Diabetes Mellitus by University of Utah is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus by University of Utah, or all of them as a file.
02

Study summary

The goal of this project is to understand the factors that affect skin temperature (e.g., tissue above amputation site, and opposite foot) in people with amputation and diabetes. This project will also test the effects of 'shock-absorbing' prosthesis on skin temperature responses.

Read the detailed description

The overall goal of this project is to understand the factors that affect impaired temperature control in individuals with a leg amputation for areas vulnerable to damage, such as the tissue above the amputation site and the opposite intact foot. Abnormal tissue temperature is associated with risks for tissue damage, such as ulcers and pressure sores, especially in people with diabetes. In this study, we aim to study the effects of biomechanics and vascular physiology on tissue temperature responses. We will also determine the effectiveness of prosthetic shock-absorbing components in protecting the tissue from damage.

It is hypothesized that the temperatures of tissues above the amputation site and in the opposite intact foot are associated with mechanical factors during walking, such as shear forces and work (i.e., energy). It is also hypothesized that impaired temperature regulation, especially in people with diabetes, is associated with poor vascular function that inhibits effective blood circulation and oxygen delivery to affected tissues. Lastly, it is hypothesized that walking with a shock-absorbing prosthetic component can improve comfort and improve temperature regulation of tissues above the amputation site.

This project will recruit 40 individuals with a unilateral transtibial (below-knee) amputation, divided into two groups: with and without diabetes. All individuals will be given two sets of prostheses: with and without a shock-absorbing pylon (SAP). SAP is a modular prosthetic component that connects the socket and the foot components and allows added compression and twisting along the pylon. In both sets of prostheses conditions, the participants will wear the same foot component provided by the research team. For each of the two sets of prostheses (with and without SAP), the participants will make up to 5 visits to the laboratory (i.e., up to 10 total visits for the entire protocol). Each visit will involve data collections under a variety of walking tasks, such as walking on various slopes and turning. The same data collections will be repeated with the other set of prostheses.

03

Conditions studied

  • Amputation
  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a unilateral transtibial amputation, divided into two groups (with and without diabetes)
  • Participants must classify as Medicare class K2 or higher (who can traverse low-level environmental barriers such as curbs, stairs or uneven surfaces).
  • Participants must have undergone amputation at least 6 months prior.
  • They must have the ability to walk for at least 10 continuous minutes without undue fatigue.

Exclusion criteria

Exclusion Criteria:

  • Neurological impairment that may affect walking function, such as stroke, severe traumatic brain injury, Parkinson's disease, and multiple sclerosis.
  • History of inflammatory diseases, such as Raynaud's syndrome or rheumatoid arthritis.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Rigid Pylon

    The prosthesis will be given a commercial prosthetic foot and a rigid pylon that connects the prosthetic foot to the socket.

    Device: shock-absorbing prosthesis

  • Experimental
    Shock-absorbing Pylon

    The prosthesis will be given a commercial prosthetic foot and a compressive 'shock-absorbing' pylon that connects the prosthetic foot to the socket.

    Device: shock-absorbing prosthesis

Interventions

  • Deviceshock-absorbing prosthesis

    the intervention will test the difference between rigid and shock-absorbing pylons, while the same prosthetic foot is applied in each condition.

06

What researchers measure

Primary outcomes

  1. Walking mechanics

    Mechanics of walking will be collected using a high-speed motion capture system and force-sensing platforms, which will quantify the motion of the legs and forces acting on the legs, respectively.

    Time frame: during the intervention/procedure/surgery

  2. Vascular physiology - macrocirculation

    Macrocirculation of the legs (i.e.,blood flow) will be recorded using a Doppler ultrasound probe secured over the thigh during walking

    Time frame: during the intervention/procedure/surgery

  3. Vascular physiology - microcirculation

    Microcirculation of the legs (i.e.,oxygen utility) will be recorded using near-infrared spectroscopy sensors placed on the thighs, calf, and top surface of the foot.

    Time frame: during the intervention/procedure/surgery

  4. Temperature in lower limb

    Temperatures of the skin above the amputation site and the opposite intact foot will be recorded using thermistors and a thermal imaging camera.

    Time frame: during the intervention/procedure/surgery

  5. Comfort

    Participants will complete a self-reported questionnaire to indicate comfort while walking with a prosthesis.

    Time frame: during the intervention/procedure/surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jul 2027, 37 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 37 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 13, 2024
StartActual
May 7, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 31, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06458426
Lead sponsor
University of Utah
Responsible party
Kota Takahashi (Assistant Professor, University of Utah) — Principal investigator
First posted
Jun 13, 2024
Start date
May 7, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Kota Takahashi
principal investigator · University of Utah

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion